We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.57 | -1.04% | 149.61 | 152.33 | 149.14 | 151.77 | 8,581,241 | 00:01:52 |
From May 2019 to May 2024
By Colin Kellaher
Healthcare company Grail Inc. on Wednesday filed with the U.S. Securities and Exchange Commission for a proposed initial public offering.
Grail's filing indicates it plans to raise $100 million, although that figure is often used as a placeholder to calculate filing fees.
The Menlo Park, Calif., company, which focuses on the early detection of cancer, said it has applied to list its shares on the Nasdaq Global Select Market under the symbol GRAL.
Grail's backers include Illumina Inc., which currently holds a 14.6% stake, and Johnson & Johnson, which owns a 7.6% interest.
Illumina launched Grail in 2016 with a group of other investors aiming to develop and market a test to detect genetic evidence of cancer in the blood.
Grail in May said it had raised $390 million in a Series D funding round.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 09, 2020 07:11 ET (11:11 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
